iKang Healthcare Group vs Meinian Onehealth
iKang Healthcare holds a firmer position because it faces lighter direct competitive pressure than Meinian, which is being squeezed by public hospitals holding about 97.4% of China's physical exam market and by discount platforms such as Taobao flash sales, based on facts assessed as of July 2026.
iKang Healthcare Group
Chinese health screening chain running 150+ physical centers, private since 2019
Meinian Onehealth
China's largest chain of physical health checkup and screening centers
Dimension by dimension
| Dimension | iKang Healthcare Group | Meinian Onehealth |
|---|---|---|
| Staying power of the core checkup business | iKang runs more than 150 centers and is described as holding steady, though with some caveats. | Meinian runs licensed screening centers in over 100 cities but is described as being losing its protection overall. |
| Exposure to AI absorbing the product | iKang's physical checkup service is also rated unlikely to be absorbed by AI. | Meinian's physical checkup service is rated unlikely to be absorbed by AI. |
| How easily a giant could copy them | A larger player copying iKang's model is also rated possible. | A larger player copying Meinian's model is rated possible. |
| Pressure from competitors | iKang competes directly with Meinian and faces some contest from Ciming and hospital VIP checkup units, but no confirmed loss of business is documented. | Public hospitals hold about 97.4% of China's physical exam market, and discount platforms like Taobao flash sales are cutting into Meinian's pricing power. |
| Overall market strength | iKang operates more than 150 centers and faces no confirmed loss of business, indicating a firmer market footing than Meinian as of July 2026. | Meinian's revenue rose 26.4% in 2023 but then fell 1.76% in 2024 and 3.20% in 2025, while public hospitals control about 97.4% of China's physical exam market, squeezing its position. |
| Financial trend visibility | iKang's only available figures date to its 2019 go-private deal, valuing it at US$1.5 billion at US$20.60 per ADS, with no recent public revenue reported since then. | Meinian's revenue rose 26.4% in 2023 but then fell 1.76% in 2024 and 3.20% in 2025, showing a shrinking trend. |
Questions people ask
- Is Meinian Onehealth's revenue growing or shrinking?
- Meinian's revenue jumped 26.4% in 2023 but then fell 1.76% in 2024 and another 3.20% in 2025. iKang does not report public revenue figures since it went private in 2019.
- Could AI replace Meinian or iKang's checkup services?
- Both companies are marked unlikely to have their core service absorbed by AI, since physical health screening requires in-person equipment and staff. Neither Meinian nor iKang currently shows signs of AI-driven disruption to their basic offering.
- Why did iKang go private?
- iKang left NASDAQ in a 2019 buyout that valued the company at US$1.5 billion, with shares bought back at US$20.60 per ADS versus its 2014 IPO price of $14.00. That transaction remains the last major public financial data point available for iKang.